Role of Biomarkers in Disease Progression in Samples From Patients With Acute Myeloid Leukemia
|ClinicalTrials.gov Identifier: NCT01500499|
Recruitment Status : Completed
First Posted : December 28, 2011
Last Update Posted : May 18, 2016
RATIONALE: Studying samples of blood, tissue, and bone marrow from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
PURPOSE: This research trial studies the role of biomarkers in disease progression in samples from patients with acute myeloid leukemia.
|Condition or disease||Intervention/treatment|
|Leukemia||Genetic: gene expression analysis Genetic: gene rearrangement analysis Genetic: polymerase chain reaction Genetic: protein analysis Genetic: western blotting Other: laboratory biomarker analysis Other: mass spectrometry|
- To determine the subcellular localization of the MLL-AF1q fusion protein in leukemia cells.
OUTLINE: Cryopreserved specimens are analyzed for MLL-AF1q fusion protein and AF1 gene expression by mass spectrometry, western blot analysis, semi-quantitative PCR, and qPCR.
|Study Type :||Observational|
|Estimated Enrollment :||20 participants|
|Official Title:||The Role of AF1q in Progression of Leukemia|
|Study Start Date :||December 2011|
|Actual Primary Completion Date :||May 2016|
- Subcellular localization of the MLL-AF1q fusion protein in leukemia cells
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01500499
|Principal Investigator:||Julie D. Saba, MD, PhD||Children's Hospital & Research Center Oakland|